Navigation Links
Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
Date:4/17/2012

BOSTONAdding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) an approach approved by the FDA in 2006 did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.

The study is being published in the April 18 Journal of the American Medical Association, a these issue on comparative effectiveness research.

"Effectiveness research examines the impact of treatments when they are used in day-to-day practice in ordinary circumstances," says the study's senior author, Deborah Schrag, MD, MPH, of Dana-Farber. "First, we found that bevacizumab was not universally adopted after its FDA approval. Second, the addition of bevacizumab did not provide any substantial survival advantage when added to standard chemotherapy."

Schrag will present the findings at a JAMA media briefing at the National Press Club in Washington on Tuesday, Apr. 17, 9:15 am. A separate video commentary is available on request.

A previous trial found that adding bevacizumab to the standard two-drug treatment for NSCLC the chemotherapy agents carboplatin and paclitaxel improved survival in many patients with advanced cases of the disease, but not those aged 65 years or older, the study authors write. In the new study, Schrag and her colleagues measured survival rates in patients who received bevacizumab-carboplatin-paclitaxel therapy and in two groups of patients who received carboplatin-paclitaxel therapy one group receiving it in 2006-2007, the other in 2002-2005.

They found that the median overall survival was 9.7 months for patients receiving the three-drug combination compared with 8.9 months for the 2006-2007 standard-therapy group, and 8.0 months for the 2002-2005 standard-therapy group. The probability of surviving for one year was 39.6 percent for those who received the three drugs vs. 40.1 percent for the 2006-2007 standard-therapy group, and 35.6 percent for the 2002-2005 standard-therapy group. Controlling for factors that can skew the results, the authors did not find a significant difference in overall survival between patients treated with bevacizumab and those treated only with standard chemotherapy.

Based on these results, the authors recommend that bevacizumab should not automatically be administered together with carboplatin-paclitaxel for older patients with NSCLC. They continue that clinicians should exercise caution in making treatment recommendations and use bevacizumab judiciously for their patients.

The authors also advise that for cancers like NSCLC that tend to arise in elderly patients, clinical trials of potential new therapies should include an adequate number of older patients and ensure that data for these patients is analyzed.


'/>"/>

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
617-632-5665
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Twitter Adding to Stigma of Epilepsy, Study Says
2. Adding Lovenox Didnt Reduce Blood Clot Death Risk in Study
3. Adding Psychotherapy to Meds Helps Kids With OCD
4. Heart Attack Damage Not Reduced by Adding Balloon Pump to Angioplasty
5. Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
6. Adding a stent during minimally invasive surgery to repair aneurysms prevents recurrence
7. Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinux
8. Adding Folate to Tortilla Flour Might Cut Birth Defects Among Hispanics
9. Breast cancer surgery patients benefit from adding radiation therapy
10. Adding ipilimumab to standard chemotherapy treatment for late-stage lung cancer may improve survival
11. Adding Surgery to Meds May Help Diabetics With Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Resoundant, Inc., the developer of Magnetic ... annual customer education symposium, a world-class learning conference that offers educational content designed ... 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations for ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of all holidays (IBT World Travel Trends Report). As travelers visit both urban ... range in temperatures, and prolonged sun exposure. In response, the outdoor industry has ...
(Date:3/28/2017)... ... ... Alert Sentry Group LLC., a leader in the Personal Emergency Response System industry, introduced ... Plus. These iSAFE products are the most affordable and most advanced medical alert systems ... direct GPS Location and two-way calling with the push of a button on a ...
(Date:3/28/2017)... ... , ... The Radiology Business Management Association (RBMA) is pleased to ... executive director. Mr. Still was selected through a careful months-long search by the RBMA ... known to our members, has been a part of building the RBMA since 1992,” ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , a provider ... and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and ... biometric face recognition to enable users to check in and out from anywhere ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... . This new business entity, Emosis Ltd, headquartered in ... and development of novel assays complementing the mother company existing technology ... support commercialization and sales development of Emosis kits. ... This strategic move starts building Emosis ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... Elysium Health joins major pharmaceutical companies to ... Cambridge academic scientists through ... Institute today announces Elysium Health as a partner to the ... collaborative projects with academic researchers in Cambridge ... major research investment outside the U.S. for the ...
Breaking Medicine Technology: